Instrument Inactif

Communiqués Realex Properties Corp.

Actions

RP

CA7560415050

Cours en clôture Toronto S.E.
- CAD - Graphique intraday de Realex Properties Corp.

Communiqués

16/02/16 Realex Properties : RepliCel Announces CEO Update MW
05/06/15 Realex Properties : RepliCel Life Sciences Announces Participation in 23rd World Congress of Dermatology, Vancouver, BC PR
21/05/15 Realex Properties : RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference PR
07/05/15 Realex Properties : RepliCel Life Sciences Selected to Present at Cavendish Global Health Impact Forum PR
29/04/15 Realex Properties : RepliCel Announces 2014 Fourth Quarter and Year-End Financial Results PR
15/04/15 Realex Properties : RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis PR
08/04/15 Realex Properties : RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates PR
02/04/15 Realex Properties : RepliCel Life Sciences Applies to Extend Warrant Expiry Dates PR
12/03/15 Realex Properties : RepliCel Life Sciences in Japan for Key Industry Meetings PR
20/01/15 Realex Properties : RepliCel Life Sciences to Present at 11th Annual Phacilitate Cell & Gene Therapy Forum in Washington, DC PR
07/01/15 Realex Properties : RepliCel Life Sciences to Present at Biotech Showcase 2015 in San Francisco PR
22/12/14 Realex Properties : Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness PR
10/11/14 Realex Properties : R. Lee Buckler: How RepliCel Is Harnessing the Awesome Power of Cell Therapy MW
02/10/14 Realex Properties : RepliCel to Present Clinical Trial Update at Stem Cell Meeting on the Mesa Partnering Forum in California MW
13/09/14 Realex Properties : RepliCel Retains Market-Making Services MW
20/05/14 Realex Properties : RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness MW
27/02/14 RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine MW
Aucun résultat pour cette recherche